Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962325 | 0.82 | LOXL2 (0.34) | CA2PTGS2PTGS1CA12CA1 | |
| SCHEMBL22012739 | 0.78 | PLK1 (0.36) | PLK1LOXL2MAOALOX | |
| SCHEMBL22014859 | 0.77 | CA2 (0.41) | CA2PTGS2PTGS1CA12CA1 | |
| SCHEMBL22020696 | 0.73 | PTGS2 (0.38) | CA2PTGS2PTGS1CA12CA1 | |
| SCHEMBL21962672 | 0.71 | ALDH1A1 (0.47) | CA2PTGS2PTGS1CA12CA1 | |
| SCHEMBL19506011 | 0.68 | CA2 (0.38) | CA2PTGS2PTGS1 | |
| SCHEMBL4610069 | 0.68 | STAT3 (0.41) | CA2PTGS2CA12CA1CA9 | |
| SCHEMBL7144005 | 0.64 | CA2 (0.44) | CA2PTGS2PTGS1CA12CA1 | |
| SCHEMBL19475269 | 0.64 | CA2 (0.37) | CA2 | |
| SCHEMBL19474971 | 0.64 | CA2 (0.49) | CA2CA12CA1CA9LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 1210/4885PTGS2 1219/4885PTGS1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.